Receive The Newest Study Notifications

AGOURA HILLS, Calif., Dec. 23, 2019 (GLOBE NEWSWIRE) — Mateon Therapeutics Inc. (OTCQB:MATN), dedicated to the development of innovative treatments for cancer, today announced that the multi-institutional OXI1222 study in people with previously treated relapsed acute...

HOPKINTON, Mass., Dec. 26, 2019 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, today...

CHESTERBROOK, Pa., Dec. 23, 2019 (GLOBE NEWSWIRE) -- Trevena, Inc. (TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced the initiation of a...

NEW YORK, Dec. 23, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals Inc. (Nasdaq:PGNX), an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and follow cancer, today announced positive top line results from the...

IRVINE, Calif. & BASEL, Switzerland--(BUSINESS WIRE)--Dec 23, 2019-- Urovant Sciences (Nasdaq: UROV), announced today that the first patient has been enrolled in a Phase 2a study evaluating the efficacy and safety of URO-902, a novel gene therapy product, in...

Expects to report Trilogy 1 topline results in January 2020 with topline results for Trilogy 2 still expected by the end of January 2020 LAVAL, Québec, Dec. 23, 2019 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti or the “Company”) (NASDAQ: ACST – TSX-V: ACST), a...

– Submission Based on Positive Pivotal HER2CLIMB Trial Results Recently Presented at the 2019 San Antonio Breast Cancer Symposium and Published in the New England Journal of Medicine – – FDA Granted Breakthrough Therapy Designation for Tucatinib in Locally Advanced or...

  ATLANTA, Dec. 23, 2019 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that it has received authorization from the U.S. Food and Drug Administration (FDA) pursuant to an...

TEL AVIV, Israel, Dec. 23, 2019 /PRNewswire/ -- Cellect Biotechnology Ltd. (NASDAQ: APOP), a developer of innovative technology to enable the functional selection of stem cells, has received approval to initiate the trial in the U.S. to evaluate the safety and...

BUFFALO GROVE, Ill.--(BUSINESS WIRE)--Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today the initiation of PHALCON-HP....

LAGUNA HILLS, Calif.--(BUSINESS WIRE)--PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that both...

– Top-line statistical results expected mid-2020 – – Company to meet with FDA in January 2020 regarding Phase 3 clinical development plan – Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of...

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases, today announced...

  Imeglimin met its key efficacy endpoint of HbA1c reduction, demonstrating how its unique dual mechanism of action was observed to show added efficacy benefits in combination with existing hypoglycemic agents In particular, Imeglimin was observed to demonstrate...

Patient is the fourth dosed in Phase 2 trial of AVR-RD-01, an investigational gene therapy for Fabry disease plato is AVROBIO’s platform for worldwide gene therapy commercialization CAMBRIDGE, Mass.--(BUSINESS WIRE)--AVROBIO (NASDAQ: AVRO) (the “Company”), a leading...

– New pivotal trials will evaluate the combination of cabozantinib and atezolizumab in patients with advanced non-small cell lung cancer, castration-resistant prostate cancer and renal cell carcinoma – – Collaboration based on data from phase 1b COSMIC-021 trial –...

Clinical trial application for pivotal JTA-004 Phase III study submitted Start patient enrollment anticipated early 2020 with topline results expected in Q2 2021 BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the leading biotech company focused on the...

MIN-117 study did not meet its primary (MADRS) and key secondary (HAM-A) endpoints MIN-117 was generally well-tolerated with a safety profile comparable to placebo Company to host conference call at 5:00 p.m. today (dial-in information below) WALTHAM, Mass., Dec. 18,...

– New pivotal trials will evaluate the combination of cabozantinib and atezolizumab in patients with advanced non-small cell lung cancer, castration-resistant prostate cancer and renal cell carcinoma – – Collaboration based on data from phase 1b COSMIC-021 trial –...

First-in-human safety and tolerability Phase 2 clinical trial ‘Danube’ in 36 patients met primary objective of selecting the dose of NCX 4251 for further development NCX 4251 0.1% once daily (QD) treatment was selected to advance into larger Phase 2b clinical trial,...